Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| GlaxoSmithKline | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus.
The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.
This questionnaire is a follow-on to the "MM and COVID-19" questionnaire.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MGUS, SMM, MM Patients or their Caregivers | Eligible participants will be asked to create a free patient profile on the HealthTree Cure Hub (www.healthtree.org) or use their existing patient profile. The creation of a HealthTree Cure Hub patient profile will serve as a screen for eligibility. Patients will complete a one-time questionnaire found on the HealthTree Cure Hub. Telephone assistance can be provided as needed. The questionnaire will take 20-30 minutes to complete. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Questionnaire | Behavioral | Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life. |
| Measure | Description | Time Frame |
|---|---|---|
| COVID-19 Diagnosis and Treatment | Describe how patients diagnosed with COVID-19 were treated for the virus. | Up to one year |
| Changes to Myeloma Treatment and Care | Describe which treatments were changed and how care was affected as a result of COVID-19 | Up to one year |
| Health and Fitness | Describe how COVID-19 impacted patient's health and fitness | Up to one year |
| Quality of Life (QOL) Distress Screening tool | Describe how patients rate their level of concern on psychosocial, practical, and physical needs during the COVID-19 pandemic using the Cancer Support Community's CancerSupportSource distress screening tool. | Up to one year |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical Trial Familiarity | Describe how familiar patients are with multiple myeloma clinical trials. | Upon enrollment |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Patients diagnosed with MGUS, smoldering myeloma, or multiple myeloma.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nathan Sweeney, PhD | Contact | 18007091113 | nathan@healthtree.org |
| Name | Affiliation | Role |
|---|---|---|
| Nathan Sweeney, PhD | HealthTree Foundation | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| HealthTree.org (Online) | Recruiting | Lehi | Utah | 84043 | United States |
The HealthTree foundation values responsible and ethical sharing of data from clinical trials. De-identified patient responses to the questionnaire will be aggregated and shared back with the patient. Additionally, portions of the de-identified results will be shared with the research community through publications (abstracts, reports, manuscripts).
Not provided
Visit the HealthTree Foundation's online patient portal: HealthTree Cure Hub For Multiple Myeloma
| Type | Date | Date Unknown |
|---|---|---|
| Release | Mar 23, 2022 | |
| Reset | Mar 24, 2022 | |
| Release | Mar 25, 2022 | |
| Reset | Apr 5, 2022 | |
| Release | Aug 4, 2022 | |
| Reset | Jul 3, 2023 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Mar 23, 2022 | Mar 24, 2022 | |||
| Mar 25, 2022 |
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| D000075122 | Smoldering Multiple Myeloma |
| D008998 | Monoclonal Gammopathy of Undetermined Significance |
| D018352 | Coronavirus Infections |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D011795 | Surveys and Questionnaires |
| ID | Term |
|---|---|
| D003625 | Data Collection |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Apr 5, 2022 |
| Aug 4, 2022 | Jul 3, 2023 |
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D011230 | Precancerous Conditions |
| D006942 | Hypergammaglobulinemia |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |